Fresenius Kabi launches generic Precedex
Fresenius Kabi is introducing dexmedetomidine hydrochloride in 0.9% sodium chloride injection.
The product, which is the generic of Hospira's Precedex, is approved for intravenous use and is a relatively selective alpha2-adrenergic agonist indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.
Fresenius Kabi’s dexmedetomidine hydrochloride in 0.9% sodium chloride injection is available in 20 mL vials, as well as 50 mL and 100 mL bottles. The introduction of these dexmedetomidine presentations complement Fresenius Kabi’s previously available dexmedetomidine HCl injection 2 mL single dose vials.
“Fresenius Kabi is pleased to again expand our anesthesia and analgesia portfolio with the addition of dexmedetomidine in a convenient, ready-to-use formulation,” John Ducker, president and CEO of Fresenius Kabi USA said. “Fresenius Kabi is committed to enabling broader access to affordable, critical medications for clinicians and their patients.”
The product, which is the generic of Hospira's Precedex, is approved for intravenous use and is a relatively selective alpha2-adrenergic agonist indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.
Fresenius Kabi’s dexmedetomidine hydrochloride in 0.9% sodium chloride injection is available in 20 mL vials, as well as 50 mL and 100 mL bottles. The introduction of these dexmedetomidine presentations complement Fresenius Kabi’s previously available dexmedetomidine HCl injection 2 mL single dose vials.
“Fresenius Kabi is pleased to again expand our anesthesia and analgesia portfolio with the addition of dexmedetomidine in a convenient, ready-to-use formulation,” John Ducker, president and CEO of Fresenius Kabi USA said. “Fresenius Kabi is committed to enabling broader access to affordable, critical medications for clinicians and their patients.”